REG - Futura Medical PLC - Block Listing Six Monthly Return

Futura MedicalAnnouncement

Tue 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251209:nRSI8883Ka&default-theme=true

RNS Number : 8883K  Futura Medical PLC  09 December 2025

09 December 2025

Futura Medical plc

("Futura", "the Group" or the "Company")

Block Listing Six Monthly Return

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that
specialises in the development and global commercialisation of innovative and
clinically proven sexual health products, makes the following update on its
block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies. All figures relate to options over Ordinary Shares of 0.2 pence
each (Ordinary Shares).

 

 Name of applicant:                                                                  Futura Medical Plc
 Name of scheme(s):                                                                  Unapproved Share Option Scheme

                                                                                     Unapproved Share Incentive Scheme

                                                                                     EMI Share Option Scheme

                                                                                     LTIP Scheme
 Period of return:                         From:                                     1 June 2025         To:                 8 December 2025
 Balance of unallotted securities under scheme(s) from previous return:              18,528,545
 Plus:  The amount by which the block scheme(s) has been increased since the         USOS: nil
 date of the last return (if any increase has been applied for):

                                                                                     USIS: nil

                                                                                     EMI: nil

                                                                                     LTIP: nil
 Less:  Number of securities issued/allotted under scheme(s) during period:          USOS: nil

                                                                                     USIS: nil

                                                                                     EMI: nil

                                                                                     LTIP: 2,290,975

 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:          16,237,570
 Number and class of securities originally admitted and the date of admission        USOS Total: 3,882,912

                                                                                     814,424 25 May 2011

                                                                                     1,202,280             8 October 2013

                                                                                     1,466,208             25 May 2017

                                                                                     400,000                30 May 2018

                                                                                     USIS Total: 425,000

                                                                                     425,000 30 November 2018

                                                                                     EMI Total: 8,112,088

                                                                                     1,520,576             25 May 2011

                                                                                     1,467,720             8 October 2013

                                                                                     1,893,792             25 May 2017

                                                                                     790,000                30 May 2018

                                                                                     1,340,000             30 November 2018

                                                                                     1,100,000             2 February 2023

                                                                                     LTIP Total:  15,035,617

                                                                                     4,444,942            2 February 2023

                                                                                     10,590,675          3 November 2023

 

Contacts:

 Futura Medical plc                          Alex Duggan                                             investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                             Chief Executive Officer

                                                       +44 (0)1483 685 670
                                             Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                             Finance Director and COO

 Panmure Liberum                             Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser

 and Broker

 Turner Pope Investments (TPI) Ltd - Broker  Guy McDougall, Andrew Thacker                           +44 (0) 20 3657 0050

 Alma Strategic Communications               Rebecca Sanders-Hewett, Sam Modlin, Emma Thompson       +44 (0)20 3405 0205

                                                                                                     futura@almastrategic.com

 

Notes to Editors:

 

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and development products WSD4000
and Eroxon(®) Intense. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in sexual health
products.

 

Sexual health issues are prevalent in both men and women. Erectile Dysfunction
("ED") impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40. Around 60% of women experience at least one
symptom of sexual dysfunction, and only one in four women seek professional
help, and remain chronically underserved.

 

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of ED. The highly differentiated product, which is the only
topical gel treatment for ED available over the counter and helps men get an
erection in ten minutes, addresses significant unmet needs in the ED market.
Eroxon(®) has been nominated for a number of healthcare industry awards and
has won two to-date.

 

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

 

WSD4000 is a topical treatment designed for the symptoms of impaired sexual
response and function in women. There is currently no regulatory approved OTC
treatment available for impaired sexual response and function in women.
WSD4000 has the potential to be an effective, breakthrough treatment for the
common symptoms associated with impaired sexual response and function, such as
lack of desire, arousal and lubrication.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRTLBATMTAMBRA



            Copyright 2019 Regulatory News Service, all rights reserved